Monday, August 31, 2026

Moderna Stock Bearish By 5% So Far Today

ViaNews Editorial Team

December 24, 2020

Moderna Stock Bearish By 5% So Far Today

Shares of Moderna dropped 5.08% to $123.72 at 11:40 EST on Thursday, following last session's upward trend. NASDAQ Composite is rising 0.11% to $12,785.60, following last session's downward trend, This seems, as yet, a somewhat positive trend exchanging session today.

Moderna's last close was $130.34, 44.28% below its 52-week high of $178.50.

Moderna's Sales

Moderna's sales growth is 1841.7% for the present quarter and 19117.5% for the next. The company's growth estimates for the ongoing quarter is a negative 2.7% and positive 660% for the next.

Moderna's Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna's Stock Yearly Top and Bottom Value

Moderna's stock is valued at $123.72 at 11:40 EST, way below its 52-week high of $178.50 and way above its 52-week low of $17.68.

Moderna's Moving Average

Moderna's worth is higher than its 50-day moving average of $119.90 and way higher than its 200-day moving average of $81.71.

Previous days news about Moderna

Philippines to start vaccine talks with Moderna by year-end: CNN. According to Bloomberg Quint on Mon Dec 21, "The Philippines will start talks with Moderna Inc. on or before Dec. 30 to secure supply of the company's coronavirus vaccine, Foreign Affairs Secretary Teodoro Locsin said Monday.", ""Moderna is interested in giving an allocation," he said in a live-streamed interview with CNN Philippines, citing Philippine ambassador to the U.S. Jose Manuel Romualdez."

Moderna, biontech post worst day for vaccine stocks in a month. According to Bloomberg Quint on Tue Dec 22, "Moderna, BioNTech and Pfizer have each traded off their highs since their vaccines received regulatory clearance.", "Moderna Inc. and BioNTech SE both fell more than 9% in heavy volume as the vaccine makers saw their worst day in the stock market since late November."

Health Canada authorizes Moderna Covid-19 vaccine. According to Business Insider on Wed Dec 23, "OTTAWA, ON, Dec. 23, 2020 /CNW/ -Today, Health Canada authorized the second COVID-19 vaccine in Canada, manufactured by Moderna.", "Moderna is currently conducting additional studies in children from 12 years of age and older, and this indication could be revised in the future to include children if the data from these studies support it."

Moderna shot gets approval in Canada’s expanding vaccine effort. According to Bloomberg Quint on Wed Dec 23, ""The different storage and handling requirements of the Moderna Covid-19 vaccine mean that it can be distributed to isolated and remote communities, including the territories."", "Approval of the Moderna shot will allow Canada to expand its vaccination campaign beyond initial inoculation sites in urban centers. "

Canada authorizes Moderna vaccine. According to MarketWatch on Wed Dec 23, "Shares of Moderna Inc. were down 0.1% in trading on Wednesday after it said Canada authorized its COVID-19 vaccine for adults. "

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI's Trust Gap: Microsoft-Mistral Ecosystem Expansion Meets a Governance Deficit in Agentic Adoption
Microsoft is deepening its AI platform bet through simultaneous moves — expanding its Mistral partnership (Copilot Studio, Foundry, European infrastructure capacity) and deepening enterprise AI governance ties with Manulife — just as independent research (Google Cloud, VentureBeat, Box) shows enterprises racing toward agentic AI adoption (100% planned within two years) while data access and trust in agent decisions lag badly (average 45% data access, only ~half trust agent outputs). The result is a structural mismatch between platform-vendor momentum and enterprise readiness to actually govern and trust the agents being deployed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
Same entity (Morgan Stanley & Co. LLC), same metric (net_income), same fiscal period (Q1 2026), same observation date (2026-03-31), but vastly different values: $5.567 billion vs. $5.57. These cannot coexist for the same time period. Fact B appears to be a data entry error (possible missing decimal placement: 5.57 should likely be 5,567,000,000 or a per-share figure incorrectly entered as total).
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,257 source documents archived
Query this data → isubstrate.com